SCHEMBL10003698

SCHEMBL10003698

CCOC(=O)c1c(OCC(F)(F)F)c2cc(NC(=O)c3ccc(F)cc3)c(C)nc2n1C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.48
▸ LMNA P02545 2/20 0.48
▸ ADORA2A P29274 4/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ HPGD P15428 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ TSHR P16473 1/20 0.42
▸ ADORA3 P0DMS8 4/20 0.41
▸ ADORA1 P30542 3/20 0.41
▸ SMN1; SMN2 Q16637 4/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ GAA P10253 1/20 0.40
▸ KMT2A Q03164 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003177 0.92 SMN1; SMN2 (0.43) KDM4ELMNAADORA2AALDH1A1HPGD
SCHEMBL10003062 0.91 LMNA (0.46) KDM4ELMNAADORA2AALDH1A1HPGD
SCHEMBL10003080 0.91 ALDH1A1 (0.42) KDM4ELMNAALDH1A1HPGDMAPT
SCHEMBL10003380 0.85 KDM4E (0.49) KDM4ELMNAADORA2AALDH1A1HPGD
SCHEMBL10002933 0.83 ALDH1A1 (0.40) KDM4ELMNAALDH1A1HPGDMAPT
SCHEMBL10003390 0.83 HTT (0.41) LMNAALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL10004429 0.83 LMNA (0.51) KDM4ELMNAADORA2AALDH1A1HPGD
SCHEMBL10003336 0.83 SMN1; SMN2 (0.41) KDM4ELMNAADORA2AALDH1A1HPGD
SCHEMBL10003799 0.83 NPC1 (0.43) KDM4ELMNAALDH1A1HPGDMAPT
SCHEMBL10004018 0.82 ALDH1A1 (0.41) KDM4ELMNAALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH KDM4E 405/4885LMNA 4452/4885ADORA2A 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback